Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 18k
7 March 2019
Question for written answer E-001239-19
to the Commission
Rule 130
Francis Zammit Dimech (PPE)

 Subject:  Access to innovative cancer drugs
 Answer in writing 

The Institute of Cancer Research recently published a report entitled ‘From patent to patient — analysing access to innovative cancer drugs’. The EU is making big strides in research and innovation by testing new medication and potential vaccines for cancer. That said, the report confirms that it is currently taking longer for new treatments to reach cancer patients than it did one decade ago.

It is crucial that the latest advances in cancer treatment are offered to EU patients as quickly as possible.

What is the Commission doing to protect EU citizens’ right of access to preventive healthcare and medical treatment, and what is it doing to guarantee that patients have equal access to the latest generation of cancer vaccines and medicines under the most favourable conditions?

What implications will the relocation of the European Medicines Agency (EMA) have on the regulatory system for medicines following the UK’s withdrawal from the European Union?

Last updated: 2 April 2019Legal notice